News

The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).
At the Virtual ACCC Annual Meeting & Cancer Center Business Summit, experts convened to discuss real-world experiences and challenges associated with the pandemic.
At the Virtual ACCC Annual Meeting & Cancer Center Business Summit, a panel of healthcare professionals discussed real-world experiences on the challenges of COVID-19 and its effect on cancer care.
Researchers found that artificial light at night may disrupt circadian rhythm, leading to an increased risk of developing thyroid cancer.
Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
Among patients with NSCLC, first-line nivolumab plus ipilimumab combined with chemo yields greater OS than chemo alone.
From March 1-5, cancer care professionals from a variety of specialties and care delivery settings will convene virtually for the ACCC 47th Annual Meeting & Cancer Center Business Summit.
The FDA has approved cemiplimab-rwlc for the first-line treatment of patients with advanced NSCLC with high PD-L1 expression and no EGFR, ALK, or ROS1 aberrations.
Stay in the know.
OncNet Newsletter